The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A real-world evidence of immunotherapy adoption in non-small cell lung cancer (NSCLC) treatment and its transition from platinum-refractory to the first line of therapy.
 
Pedro De Marchi
Honoraria - Sanofi
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Merck; Merck Sharp & Dohme; Novartis; Roche; Takeda
Research Funding - Amgen; AstraZeneca; Merck Sharp & Dohme; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche
 
Pedro Nazareth Aguiar
Stock and Other Ownership Interests - Blau Farmaceutica
Honoraria - AstraZeneca/MedImmune; Boehringer Ingelheim; Merck; SERVIER
Consulting or Advisory Role - Amgen
 
Rafael Paes
Speakers' Bureau - MSD Oncology
 
Matheus Costa e Silva
Employment - Grupo Oncoclínicas; Rede D'Or São Luiz
 
Isabella Favato Barcelos
No Relationships to Disclose
 
Gabriela Monte Tenorio Taveira
No Relationships to Disclose
 
Tatiane Caldas Montella
No Relationships to Disclose
 
Bruno Lemos Ferrari
No Relationships to Disclose
 
Carlos H. Barrios
Stock and Other Ownership Interests - MedSIR; Tummi
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Eisai; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Zodiac Pharma
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Eisai; GlaxoSmithKline; Libbs; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech; United Medical
Research Funding - AB Science (Inst); Abbvie (Inst); Abraxis BioScience (Inst); Amgen (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clinica Atlantis (Inst); Covance (Inst); Daiichi Sankyo (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); ImClone Systems (Inst); INC Research (Inst); inVentiv Health (Inst); Janssen (Inst); LEO Pharma (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merrimack (Inst); Millennium (Inst); Mylan (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Polyphor (Inst); Roche/Genentech (Inst); Sanofi (Inst); Shanghai Henlius Biotech (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Carlos G. M. Ferreira
No Relationships to Disclose
 
Rodrigo Dienstmann
Employment - Oncoclínicas
Consulting or Advisory Role - Boehringer Ingelheim; Roche
Speakers' Bureau - Amgen; Ipsen; Libbs; MSD Oncology; Roche; Sanofi; SERVIER
Research Funding - Merck